The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. ⋯ Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).